News FDA holds back MSD’s chronic cough drug again MSD will have to return to the drawing board to chart a course for US approval of its chronic cough treatment gefapixant.
R&D Proving ROI for digital endpoints The costs associated with clinical trials are a major bottleneck to drug development and affordability.
Digital Fixing clinical trial data management It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.